Uptake and safety of Sotrovimab for prevention of severe COVID-19 in a cohort and self-controlled case series study

Uptake and safety of Sotrovimab for prevention of severe COVID-19 in a cohort and self-controlled case series study

Abstract Background Sotrovimab is a neutralising monoclonal antibody (nMAB) currently available to treat extremely clinically vulnerable COVID-19 patients in England. Trials have shown it to have mild to moderate side effects, however, evidence regarding its safety in real-world settings remains ins...

Full description

Saved in:
Bibliographic Details
Main Authors: Martina Patone, Andrew JHL Snelling, Holly Tibble, Carol Coupland, Aziz Sheikh, Julia Hippisley-Cox
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:Communications Medicine
Online Access:https://doi.org/10.1038/s43856-024-00720-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items